Intuitive Surgical does not give investors many easy entry points. Tuesday’s after-hours selloff may be one of the rare exceptions worth examining carefully before the market opens.
ISRG shares dropped about 7% in after-hours trading on October 20 after reporting third-quarter earnings and revenue that beat analyst expectations. Non-GAAP EPS came in at $3.00, beating estimates by roughly $0.35, while revenue of $3.05 billion surpassed forecasts by about $140 million. So why the selloff? Two things rattled the market: a one-time charge and a deliberate decision to adjust pricing.
The results included a $450 million pre-tax charge related to an antitrust settlement, which reduced earnings by $0.99 per diluted share. That explains the gap between the adjusted figure of $3.00 and the GAAP figure of $1.49. Then there was the pricing news. Intuitive announced pricing actions intended to broaden adoption in high-volume benign procedures, with management expecting those changes, along with a policy-driven reduction in China, to reduce da Vinci instruments and accessories revenue per procedure by approximately 3% to 5% on a constant-mix basis once fully implemented.
That second item deserves more nuance than the market gave it Tuesday evening. Management said the rollout will happen country-by-country, with the complete impact expected near year-end 2027, while gross-margin effects should be modest and offset. In other words, Intuitive is deliberately trading a sliver of near-term revenue per procedure for a much larger installed base over time. That is a classic long-cycle platform move, not a distress signal.
What the Business Actually Did in Q3
Third-quarter 2026 revenue growth hit 22%, bringing total revenue to $3.05 billion, as procedure growth, system placements, and adoption of newer platforms all contributed. Management said 84% of quarterly revenue was recurring. That recurring base is the engine of the long-term thesis, not the quarterly EPS line.
Intuitive placed 546 da Vinci systems during the third quarter, up 28% from 427 a year earlier. In the U.S., da Vinci procedure growth was about 10%, and outside the U.S. it was about 20%. U.S. da Vinci procedure growth at 10% was the lowest since COVID, which gives bears something to point to. It also reflects a tough prior-year comparison rather than a structural slowdown.
For 2026, Intuitive narrowed its forecast for da Vinci procedure growth to 14% to 15%, with an expectation toward the midpoint. The range itself was cut slightly, from 13.5% to 15.5% previously, with the midpoint unchanged.
What the Valuation Looks Like Now
ISRG’s trailing price-to-earnings ratio is in the mid-40s, below levels the stock has often carried in recent years. The 52-week high is $603.88, and the stock was already roughly 27% below that level before Tuesday’s report. After the after-hours drop, the discount deepened further.
For long-term investors, the question is whether the deliberate price reduction in instruments and accessories changes the decade-long compounding story or simply resets it. Intuitive runs a business where installed systems generate recurring revenue for years. More placements, even at slightly lower per-procedure economics, compound into a larger recurring base. Management said the company exited Q3 with more than 13,200 da Vinci and Ion systems installed worldwide. That installed base grew about 13% year over year. Volume, not per-unit price, is what drives the long arc.
Risks Worth Monitoring
China’s operating environment remains challenging, with lower recent capital placements and policy-driven price reductions beginning in November. That is a real headwind, not a rounding error. U.S. procedure growth at 10% needs to reaccelerate, and management’s cited drivers, including ambulatory surgery center expansion and new indications in cardiac and breast surgery, are longer-term opportunities that will not show up in the next quarter. The antitrust settlement removes a legal overhang, but the size of the charge will weigh on GAAP comparisons.
Intuitive Surgical has spent thirty years building something that is genuinely difficult to replicate. The selloff following Tuesday’s results reflects short-term anxiety about the per-procedure revenue model, not a verdict on the surgical robotics platform itself. Investors with a multi-year horizon should distinguish between those two things before Tuesday’s reaction sets the price they pay.
Wealth Takeaway: When a dominant platform company deliberately lowers its price to expand adoption, the market often sells first and asks questions later. The more important question is whether the installed base keeps growing. At more than 13,200 systems and counting, Intuitive’s answer is not in doubt yet.
